McLeavy and colleagues [19] found that patients with ovarian cancer who underwent mainstreamed genetic testing for the BRCA1 and BRCA2 genes reported low levels of decision regret, uncertainty, or lack of control following their test. This evidence concerns the gene BRCA1 and ovarian cancer.